Through a combination of research and acquisitions, Ligand has created a partnered portfolio with a wide variety of underlying technologies. This diversification provides the added benefits of exposure to a wider variety of science, more licensing opportunities and lower impact of individual patent expiry.
Captisol® is a patent-protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).
Licensing ContactFour OmniAb® therapeutic antibody platforms, OmniRat®, OmniFlic®, OmniMouse® and OmniChicken™, that produce highly diversified, fully human antibody repertoires optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity.
Licensing ContactLTP Technology™ is a broadened novel pro-drug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver.
Licensing ContactHepDirect™ is a prodrug technology that targets the delivery of certain drugs to the liver by using a proprietary chemical modification that renders a drug biologically inactive until cleaved by a liver-specific enzyme.
Licensing ContactThe SUREtechnology Platform™, a Selexis, SA technology, is based on novel DNA-based elements that control the dynamic organization of chromatin within mammalian cells and allow for higher and more stable expression of recombinant proteins. Several programs acquired by Ligand are based on this technology.
